XBIOTECH INC. (NASDAQ:XBIT) Files An 8-K Entry into a Material Definitive Agreement

XBIOTECH INC. (NASDAQ:XBIT) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

XBiotech Inc. Exhibit
EX-2.1 2 exh_21.htm EXHIBIT 2.1 EXHIBIT 2.1   EXECUTION VERSION   [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.             Asset Purchase Agreement       Dated as of December 7,…
To view the full exhibit click here


XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody Xilonix is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a). The Company completed a Phase I and II clinical trial for MABp1 as a treatment for cancer at MD Anderson Cancer Center. The Company is also investigating MABp1 in clinical trials for other indications, including vascular disease, type II diabetes, acne and psoriasis.

An ad to help with our costs